Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $513 | $468 | $439 | $728 |
| - Cash | $297 | $381 | $155 | $183 |
| + Debt | $555 | $139 | $97 | $91 |
| Enterprise Value | $771 | $226 | $381 | $636 |
| Revenue | $55 | $1 | $0 | $0 |
| % Growth | 8,001.5% | – | – | – |
| Gross Profit | $47 | $1 | -$1 | -$1 |
| % Margin | 85.6% | 75.5% | – | – |
| EBITDA | -$262 | -$159 | -$170 | -$137 |
| % Margin | -473.3% | -23,321% | – | – |
| Net Income | -$334 | -$202 | -$198 | -$144 |
| % Margin | -605.1% | -29,558.9% | – | – |
| EPS Diluted | -5.29 | -3.93 | -5.7 | -4 |
| % Growth | -34.6% | 31.1% | -42.5% | – |
| Operating Cash Flow | -$267 | -$138 | -$147 | -$148 |
| Capital Expenditures | -$0 | -$2 | -$1 | -$0 |
| Free Cash Flow | -$267 | -$139 | -$148 | -$149 |